Table S2.

ADP sensitivity (EC₅₀) of nontreated and PKA-treated cardiomyocytes

Samples	Vs. donor	P value	95% CI, mmol/L	ns
Nontreated
	IDCM	*P = 0.041	−0.83 to −0.018	n = 4, n = 14
	MYH7mut	*P = 0.003	−1.08 to −0.23	n = 3, n = 11
	MYBPC3mut (missense)	*P = 0.010	0.14–0.98	n = 3, n = 12
	MYBPC3trunc (truncating)	*P = 0.004	0.16–0.85	n = 10, n = 28
	TNNT2mut	*P = 0.002	−1.57 to −0.36	n = 1, n = 4
	TNNI3mut	*P = 0.003	−1.54 to −0.32	n = 1, n = 4
	HCMsmn	*P = 0.038	−0.77 to 0.02	n = 5, n = 18
PKA-treated
	IDCM	P = 0.895	−0.44 to 0.39	n = 4, n = 14
	MYH7mut	P = 0.106	−0.80 to −0.08	n = 3, n = 11
	MYBPC3mut (missense)	*P = 0.032	−0.04 to 0.92	n = 3, n = 12
	MYBPC3trunc (truncating)	*P = 0.001	0.26–0.96	n = 10, n = 28
	TNNT2mut	*P = 0.001	−1.67 to −0.41	n = 1, n = 4
	TNNI3mut	*P = 0.017	−1.40 to −0.14	n = 1, n = 4
	HCMsmn	P = 0.870	−0.35 to 0.42	n = 5, n = 18

Multilevel analysis. *P < 0.05 was considered significant. N, number of samples; n, number of cardiomyocytes. Sixteen cardiomyocytes from four nonfailing hearts (donor) served as controls. HCM_smn, sarcomere mutation negative; IDCM, idiopathic dilated cardiomyopathy; MYBPC3, myosin-binding protein-C mutations; MYH7_mut, myosin heavy-chain mutations; PKA, protein kinase A; TNNI3_mut, cardiac troponin I mutation; TNNT2_mut, cardiac troponin T mutation.